Amylyx Pharmaceuticals, Inc.
AMLXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAmylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the. The company carries a $1.97B market cap, placing it firmly in the small-cap category. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Market Cap
$1.97B
Beta
-0.20
P/E (TTM)
—
P/E (Fwd)
-14.02
EPS (TTM)
$-1.54
EPS (Fwd)
$-1.27
ROE
-63.3%
ROA
-38.8%
Cash
$279.8M
Total Debt
$5.6M
Free CF
-$71.5M
52W Change
112.8%
Annual Financials
Cash vs Debt
Amylyx Pharmaceuticals, Inc. holds $279.8M in cash against $5.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$71.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -63.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $22.2M (2022) to $0 (2025), a 100% decline worth watching.
AMLX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Amylyx Pharmaceuticals, Inc.'s trajectory.